RS
SKYE icon

R Squared’s Skye Bioscience SKYE Stock Holding History

R Squared’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,782
Closed -$11.1K – 685
2025
Q4 		$11.1K Buy
+14,782
New +$21.6K 0.01% 508
2025
Q1 		– Sell
-510
Closed -$1.44K – 1559
2024
Q4 		$1.44K Buy
+510
New +$2.13K ﹤0.01% 1493

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

R Squared's SKYE Position: Q1 2026 in Review

R Squared sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 14,782 shares — an estimated $11.1K sold.

R Squared first reported a position in SKYE in Q4 2024 and held it in 2 quarters. The position peaked at $11.1K in Q4 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • R Squared reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • R Squared sold 14,782 Skye Bioscience shares in Q1 2026, an estimated $11.1K.
  • R Squared first reported a position in Skye Bioscience in Q4 2024 and held it in 2 quarters.
  • R Squared's Skye Bioscience position peaked at $11.1K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.